Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 110

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 110
---
 and 31% for the three and six months ended June 30, 2025 versus 2024, respectively, primarily due to equity grants provided to new executive officers as well as the shifting of our annual equity grant to the first quarter starting in 2025.

Amortization of Acquired Intangible Assets

The following table provides a summary of the amortization of acquired intangible assets during the periods indicated, including percent changes (dollar amounts in thousands):

Three Months EndedJune 30,% Increase / (Decrease)Six Months EndedJune 30,% Increase / (Decrease)2025202420252024Amortization of acquired intangible assets$14,322 $14,322 —%$28,644 $28,644 —%

As part of the Flexion Acquisition and the MyoScience Acquisition, we acquired intangible assets consisting of developed technology intangible assets and customer relationships, with estimated useful lives between 9 and 14 years. For more information, see Note 8, Goodwill and Intangible Assets, to our condensed consolidated financial statements included herein.

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 49

Contingent Consideration (Gains) Charges, Acquisition-related Expenses, Restructuring and Other

The following table provides a summary of the costs related to the contingent consideration (gains) charges, acquisition-related expenses, restructuring and other during the periods indicated, including percent changes (dollar amounts in thousands): 

Three Months EndedJune 30,% Increase / (Decrease)Six Months EndedJune 30,% Increase / (Decrease)2025202420252024Contingent consideration (gains) charges$(357)$1,509 N/A$(3,032)$(2,297)32%Restructuring charges— 996 (100)%— 6,531 (100)%Acquisition-related expenses991 230 100+%2,502 404 100+%Legal settlement— — N/A7,000 — N/ATotal contingent consideration (gains) charges, acquisition-related expenses, restructuring and other$634 $2,735 (77)%$6,470 $4,638 39%

Total contingent consideration (gains) charges, acquisition-related expenses, restructuring and other included net charges that decreased 77% in the three months ended June 30, 2025 versus